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Abstract
Background:  Image-guidance systems allow accurate interfractional repositioning of IMRT
treatments, however, these may require up to 15 minutes. Therefore intrafraction motion might
have an impact on treatment precision. 3D geometric data regarding intrafraction prostate motion
are rare; we therefore assessed its magnitude with pre- and post-treatment fiducial-based imaging
with cone-beam-CT (CBCT).
Methods: 39 IMRT fractions in 5 prostate cancer patients after 125I-seed implantation were
evaluated. Patient position was corrected based on the 125I-seeds after pre-treatment CBCT.
Immediately after treatment delivery, a second CBCT was performed. Differences in bone- and
fiducial position were measured by seed-based grey-value matching.
Results: Fraction time was 13.6 ± 1.6 minutes. Median overall displacement vector length of 125I-
seeds was 3 mm (M = 3 mm, Σ = 0.9 mm, σ = 1.7 mm; M: group systematic error, Σ: SD of
systematic error, σ: SD of random error). Median displacement vector of bony structures was 1.84
mm (M = 2.9 mm, Σ = 1 mm, σ = 3.2 mm). Median displacement vector length of the prostate
relative to bony structures was 1.9 mm (M = 3 mm, Σ = 1.3 mm, σ = 2.6 mm).
Conclusion: a) Overall displacement vector length during an IMRT session is < 3 mm.
b) Positioning devices reducing intrafraction bony displacements can further reduce overall
intrafraction motion.
c) Intrafraction prostate motion relative to bony structures is < 2 mm and may be further reduced 
by institutional protocols and reduction of IMRT duration.
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Background
Accurate interfractional patient repositioning before pros-
tate radiotherapy has become possible in the era of Image-
Guided RadioTherapy (IGRT, [1]) with several in-room
systems such as stereotactic ultrasound [2,3], beacon
responders [4] and kV/MV cone- or fan-beam CT based
methods [5-7]. Correction of interfractional movement
improves radiation treatment accuracy if geometrical
changes are within certain limits [8,9].
However, the prostate has to be considered an inter- and
intrafractionally moving target due to permanent changes
in bladder and rectum filling [10]. Motion of the prostate
has been analysed e.g. by MR imaging. Padhani et al. have
shown by cine MRI measurements a significant displace-
ment in the antero-posterior direction [11]. Ghilezan et al.
have shown a correlation between rectal filling and intra-
fraction motion [12]. Similar data were provided by Mah
et al. and Nichol et al. [13,14].
Intensity Modulated RadioTherapy (IMRT) allows dose
escalation with creation of steep dose gradients [15]. Since
a step-and-shoot IMRT treatment fraction requires up to
15 minutes [16-18], intrafraction motion due to changing
bowel and bladder filling might be an issue [19]. Intra-
fraction motion should have an impact on PTV margins
[20,21] and dose distribution [22,23] and several
approaches are currently pursued for real time target track-
ing for compensation [24]. Such approaches allow meas-
uring intrafraction motion and include sonographic
tracking [25], tracking based on implanted fiducials
[26,27] or beacon responders [4,28] and even linac-
mounted MRI [29].
Comprehensive 3D volumetric data are, however, scarce
[12,30-32] and data published so far may overestimate
prostate mobility if an appropriate preparatory protocol is
used [33].
We therefore set out to broaden the available database for
patients undergoing an institutional preparatory protocol
designed to reduce inter- and possibly intrafraction pros-
tate motion comparing pre- and post-treatment on-board
3D imaging based on fiducials with a gantry-mounted
cone-beam CT (CBCT; Elekta Synergy®).
Methods and patients
Patients, treatment planning and delivery
78 CBCTs of 39 fractions in 5 patients with intermediate
risk prostate cancer [34,35] were evaluated. Patients were
treated with a 6 MV linear accelerator (Elekta Synergy®,
Elekta Inc., Crawley, U.K.) with step-and-shoot IMRT
plans (Corvus®, NAS/Nomos, Cranberry Township, USA;
45 Gy) as part of a combined protocol after 125I-seeds-
implantation. Stranded 125I-seeds (Rapid Strand, Oncura,
Castrop-Rauxel, Germany) were used with a diameter of
0.5 mm and a length of 3 mm. Median number of 125I-
seeds was 50.
Treatment planning CT datasets were acquired and proc-
essed by each patient using an institutional policy (mod-
erately full bladder, empty rectum using an enema before
planning CT) as published previously [2,36]. Patients
were also instructed to empty their rectum and bladder
and drink 500 ml water before each treatment fraction.
The procedure was explained and informed consent was
obtained. Typical IMRT plans consisted of 7 or 9 incident
beams.
Cone-beam volume imaging and patient repositioning
Before delivering a treatment fraction, kV CBCT volume
imaging was performed. Approximately 610 projection
images were acquired during a 360°-rotation using the
presets of Elekta (for a single projection: 120 kV, 25 mA,
40 ms). Projections were processed to 3D volume images
by the XVI® (X-Ray Volume Imaging) software of Elekta
using "high resolution" [36]. Patient position was cor-
rected on-line based on matching the 125I-seeds [36] in the
CBCT to the planning CT images with a small alignment
clip box considering the prostate (and the 125I-seeds)
only. Matching and translational position correction was
performed by an automatic grey value algorithm included
in the XVI software and always controlled visually by a
physician. The XVI algorithm has been extensively tested
by phantom-experiments regarding accuracy in case of
matching based on ~50 fiducials also in case of physio-
logic soft tissue deformations [36,37]. Rotational errors
were not corrected. Bone position was recorded by offline
matching regarding the bony structures with an alignment
clip box considering the whole bony pelvis [36]. Immedi-
ately after IMRT delivery, a second CBCT imaging was per-
formed.
Offline image analysis and data processing
The second CBCT was evaluated offline as follows:
Changes in bone position (patient intrafraction move-
ment, considering the whole pelvis; alignment clip box
including the whole bony pelvis) and fiducial position
(overall fiducial/prostate displacement, alignment clip
box considering only the 125I-seeds/prostate) were meas-
ured by offline grey-value matching ensuring user-inde-
pendence. Prostate motion relatively to the pelvic bone
structures was calculated on a patient-to-patient basis.
Overall mean value (mv) and overall standard deviation
(SD) and median value of all translational displacements
in each direction were calculated for the matching results.
Group systematic error (M), standard deviation of the sys-
tematic error (Σ) and standard deviation of the random
error (σ) were calculated [38,39]. All data were evaluated
on a patient-by-patient basis.Radiation Oncology 2008, 3:37 http://www.ro-journal.com/content/3/1/37
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The length of the translational displacement vector was
calculated with the following formula: v = √(x2 + y2 + z2).
Results
Duration of a step-and-shoot IMRT fraction
Time between the pre- and post-treatment CBCTs was
13.6 ± 1.6 minutes (mv ± SD).
Overall intrafraction prostate displacement
Median overall displacement vector length of 125I-seeds
was 3 mm (M = 3 mm, Σ = 0.9 mm, σ = 1.7 mm; M: group
systematic error, Σ: SD of systematic error, σ: SD of ran-
dom error).
mv ± SD of overall displacement of 125I-seeds was 0.4 ± 2
mm, 1.1 ± 3.9 mm and 1.3 ± 4.5 mm in × (left-right), y
(cranio-caudal) and z (antero-posterior; AP) directions
(mean length of overall displacement vector 5.1 ± 3.9
mm).
Intrafraction displacement of bony structures
Median displacement vector of bony structures was 1.84
mm (M = 2.9 mm, Σ = 1 mm, σ = 3.2 mm).
mv ± SD of displacement of bony structures was 0.2 ± 2.0
mm, -0.3 ± 1.6 mm and -0.2 ± 4.3 mm in x, y and z direc-
tions (mean length of overall displacement vector 3.1 ±
3.9 mm).
Intrafraction displacement of prostate relative to pelvic 
bones
Median intrafraction motion of the prostate due to
changes in bladder/bowel filling (relative to bony struc-
tures) was 1.9 mm (displacement vector length; M = 3
mm, Σ = 1.3 mm, σ = 2.6 mm).
mv ± SD of intrafraction motion of the prostate due to
changes in bladder/bowel filling relative to bone struc-
tures is -0.2 ± 3.2 mm, -1.5 ± 3.7 mm and -1.5 ± 4.8 mm
in x, y and z directions (mean length of overall displace-
ment vector 5.4 ± 4.8 mm). A patient example with a rel-
ative large difference in pre- and post-treatment soft tissue
position due to a moderately enlarged rectum due to gas
that shifted during therapy is shown on Fig. 1. The
enlargement in rectal volume seen in this patient was at
the limit of what is tolerated at our department. Patients
with a larger difference in rectal filling between treatment
planning CT are taken off the treatment table and
instructed to defecate/pass gas before treatment.
All results are summarised in Table 1 and displacements
on a patient-to-patient basis are shown on Fig 2.
Discussion
Modern IGRT technologies allow precise repositioning,
target-volume-visualization and even daily re-planning
[40-42] before treatment delivery so that interfraction
motion of various target sites in the body can be consid-
ered a solved problem [43,44]. Patient- and organ
motion, however, also has an intrafractional component
which has to be considered, too. In some anatomic sites
(lung- and liver tumors, upper abdominal targets), intra-
fraction motion can be extreme due to e.g. respiratory or
cardiac motion if not addressed properly. In case of the
prostate, continuous changes in bladder and bowel filling
may cause a significant intrafraction motion component
that is currently still accounted for by PTV margins and
dose distribution. Based on measurements with the
Calypso™ system, the prostate may, in some cases, move
as much as > 3–5 mm already in the first 5–10 minutes of
the treatment [28], however with a significant individual
variation among patients [10,28]. The percentage of
patients with these extreme movements, however, is small
(3D-offset exceeding 5 mm was observed in 15% of 1157
fractions in 35 observed patients, [28]) in a patient cohort
that apparently underwent no specific preparatory proto-
col. Other groups have also published data without spec-
ifying if a preparatory protocol was used. Using 2D kV
projections and 3 implanted fiducials, Letourneau et al.
have shown a small intrafraction motion with a SD of 0.9
mm [31]. Wu et al. calculated the effect of intrafraction
motion on dose distribution and showed that intrafrac-
tion motion worsens target coverage, its effect of course
being larger for small margins than for larger margins
[32]. MRI based data already suggest that intrafraction
motion is smaller in comparison to interfraction motion,
with an expected displacement of the prostate of < 3 mm
for 20 minutes in case of patients with an empty rectum
[12,30]. However, this was not the case in patiens with a
full rectum [12,30], which underlines the importance of
using institutional protocols before planning CT and each
therapy fraction. We therefore set out to further evaluate
this parameter in the actual treatment setting in exactly
such a patient cohort that was appropriately prepared
before treatment planning CT and each treatment frac-
tion.
In this work, we analysed 3D geometric data about intra-
fraction motion of the prostate with pre- and post-treat-
ment on-board imaging based on fiducials with a gantry-
mounted cone-beam CT for the first time. The novelty of
our data lie in the 3D online volumetric assessment of
inrafraction prostate motion. We have shown that during
a single step-and-shoot IMRT fraction of about 15 min-
utes, the overall motion of the prostate is relatively small
(median displacement vector length 3 mm with a group
systematic error of 3 mm). While we could not assess spu-
rious, reversible movements of the prostate during beam-
on-time, this seems to be a less relevant event based on
on-line beacon data [10,28]. To analyse the deforma-
tional component of the motion, fiducial to fiducial map-
ping would be very interesting, however it is not possibleRadiation Oncology 2008, 3:37 http://www.ro-journal.com/content/3/1/37
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with the current vendor-provided XVI™ matching algo-
rithm and was therefore not addressed because it would
have comprised a large extent of manual matching. Qual-
itative evaluation, however, showed that the deforma-
tional component was minor in comparison to
translation and tilt and the evaluation of the matching
algorithm showed, that minor deformations do not affect
evaluation of translation and tilt [37]. However, actually
deformable matching algoritms which are able to perform
a fiducial-to-fiducial based matching are being developed
in our department and are planned to be subject of further
work. The intrafraction motion of the prostate consists of
two components: motion of the bony structures caused by
e.g. relaxation of the patient, coughing, non-compliance
etc., and motion of the soft tissue structures relative to the
bone due to e.g. changing bowel or bladder filling. The
bony motion component can be minimized by patient
education and improved immobilisation techniques with
devices such as stereotactic body frames [45], leg holder
immobilisation devices [46] or customized body pillows
formed by vacuum suction [47]. The soft tissue motion
relative to bony structures due to changing bowel and
bladder filling can be reduced by institutional policies
such as training of the patients to have an empty rectum
and a relatively full bladder before each radiation session
as suggested by other groups and used for our patients
[33]. If pre-delivery image guidance shows that, e.g., the
rectum is filled (as opposed to the planning CT), patients
can be repositioned after emptying the rectum.
The extent of prostate motion is correlated to treatment
delivery time [11]. Further reduction of IMRT delivery
Planning CT (A-C) and CBCT images of a patient immediately before (D-F) and after (G-I) an IMRT fraction Figure 1
Planning CT (A-C) and CBCT images of a patient immediately before (D-F) and after (G-I) an IMRT fraction. 
Prostate position differs due to differences in rectal filling during therapy caused by rectal gas not present on treatment plan-
ning (in this case -7.4 mm in AP, 1.1 mm in left-right and -1.0 mm in cranio-caudal directions). Planning CT was acquired due to 
the intitutional policy using enema. This patient marks the maximum unidirectional displacement observed. In general patients 
with larger differences in rectal filling between treatment planning CT and daily online cone beam CT are asked to empty their 
rectum and drink water before another treatment attempt.Radiation Oncology 2008, 3:37 http://www.ro-journal.com/content/3/1/37
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time to ~3 minutes with novel methods such as IMAT
(Intensity Modulated Arc Therapy)/VMAT (Volumetric
Modulated Arc Therapy) will reduce overall target motion
[48-50]. Given the small magnitude of intrafractional
motion and the prospect for further dramatic reduction of
treatment times in the near future, the impact of this com-
ponent on the compound positioning error will likely
lose relative importance.
Intrafraction motion has, in addition to the translational
displacement, which was analysed in this report, also rota-
tional and deformational components [51]. Intrafraction
rotation [36,52] could possibly be compensated (if neces-
sary) in the future with real time target tracking and treat-
ment tables with 6 degrees of freedom (HexaPOD™). In
this work, we did not analyse the interfraction motion of
each individual fiducial, however, studies about inter- and
intrafraction prostate deformation are currently being per-
formed with a self-developed deformable matching algo-
rithm at our department. While the translational
intrafractional motion is small in our series and is
accounted for with PTV margins of 5 mm, an additional
deformational component may well be negligible. Faster
treatment paradigms such as IMAT/VMAT may aid further
in the reduction of PTV margins.
Conclusion
a) The median length of the displacement vector of the
prostate during a ~13 min IMRT session is < 3 mm. This
amount of intrafraction motion has to be considered in
choosing PTV margins even in patient cohorts that
undergo daily online image guidance.
b) Positioning devices reducing intrafraction bony dis-
placements can further reduce overall intrafraction pros-
tate motion.
c) Intrafraction motion of the prostate represented by 125I-
seeds relative to bony structures is < 2 mm in patients
appropriately prepared according to institutional proto-
cols (full bladder, empty rectum). It may be further
reduced by reduction of IMRT duration (e.g. by IMAT;
Intensity Modulated Arc Therapy, ~ fraction time 3 min-
utes).
Overall intrafraction motion vs bony displacement only vs soft tissue displacement Figure 2
Overall intrafraction motion vs bony displacement only vs soft tissue displacement. Overall intrafraction motion 
(blue); bony displacement only (pink) and displacement of the sof tissue structures relative to the bony anatomy (yellow) on a 
patient-to-patient basis in × (left-right; abscissa) and z (AP; ordinate) directions.Radiation Oncology 2008, 3:37 http://www.ro-journal.com/content/3/1/37
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